

Editor

Tore K Kvien

Associate Editors

Francis Berenbaum

Hans Bijlsma

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Editorial office

Annals of the Rheumatic Diseases

University Medical Centre Nijmegen

Department of Rheumatology

PO BOX 9101

6500 HB Nijmegen

The Netherlands

T: +44 (0)20 7383 6250

F: +44 (0)20 7383 6668

E: ard@bmj.com

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Impact Factor: 6.411

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2008 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK.

Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: Annals of the Rheumatic Diseases, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA.

Advances in targeted therapies X

Preface

iii1 Advances in targeted therapies X

F C Breedveld, J R Kalden, J S Smolen

Consensus statement

iii2 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

D E Furst, E C Keystone, B Kirkham, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, G R Burmester, J Braun, P Emery, K Winthrop, B Bresnahan, F De Benedetti, T Dörner, A Gibofsky, M H Schiff, J Sieper, N Singer, P L C M Van Riel, M E Weinblatt, M H Weisman

Tolerance and inflammation

iii26 Th17 cells in immunity and autoimmunity

M Oukka

Clinical outcomes assessment

iii30 Why do people with rheumatoid arthritis still die prematurely?

S E Gabriel

New cell and cytokine targets II

iii35 Stem cell transplantation: a treatment option for severe systemic sclerosis?

J M van Laar, D Farge, A Tyndall

iii39 Alloreactive natural killer cells in targeting high-risk leukaemias

L Moretta, F Locatelli, A Moretta

Innate immunity and autoimmunity

iii44 Phagocytosis and antigen presentation: a partnership initiated by Toll-like receptors

J M Blander

iii50 Adding fuel to fire: microRNAs as a new class of mediators of inflammation

F J Sheedy, L A J O'Neill

iii56 Lessons from multiple sclerosis: models, concepts, observations

H Wekerle

Translational medicine: brief reports


iii61 Protection against rheumatoid arthritis by HLA: nature and nurture

A L Feitsma, A H M van der Helm-van Mil, T W J Huizinga, R R P de Vries, R E M Toes

iii64 Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies

L H Calabrese, E S Molloy

Take the pain out of research every month



Annals of the Rheumatic Diseases is the premier clinical rheumatology journal in Europe with an impressive impact factor of 5.767, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for **just £212 a year** (€314, \$403). Too much paper on your desk already? An online subscription is **just £99** (€147, \$188).

Visit group.bmj.com/group/subs-sales - your subscription to this first class journal is just a few clicks away.

ard.bmj.com

BMJ Journals

- iii66** Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction
J Kay

- iii70** The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
T Weichhart, M D Säemann

Osteoarthritis

- iii75** Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism
M B Goldring, M Otero, K Tsuchimochi, K Ijiri, Y Li

New cell and cytokine targets ii

- iii83** Interleukin 21 as a target of intervention in autoimmune disease
R Ettinger, S Kuchen, P E Lipsky
- iii87** How to cope with pathogenic long-lived plasma cells in autoimmune diseases
B F Hoyer, I M Mumtaz, T Yoshida, F Hiepe, A Radbruch
- iii90** Tolerogenic dendritic cells for autoimmune disease and transplantation
A W Thomson, P D Robbins

Biological and clinical markers

- iii97** Epigenetic mechanisms in health and disease
S M van der Maarel